Huahai Pharmaceutical announced that the company recently learned that the State Drug Administration approved the listing of Resicibizumab injections declared by the holding subsidiary Huaotai through a priority review and approval procedure to treat generalized pustular psoriatic attacks in adults. This drug is the first self-developed anti-IL-36R antibody in China. The specification is 120mg/vial, and the registered classification is Class 1 of therapeutic biological products. Up to now, the company has invested a total of about RMB 259 million in R&D on this project.

Huahai Pharmaceutical announced that the company recently learned that the State Drug Administration approved the listing of Resicibizumab injections declared by the holding subsidiary Huaotai through a priority review and approval procedure to treat generalized pustular psoriatic attacks in adults. This drug is the first self-developed anti-IL-36R antibody in China. The specification is 120mg/vial, and the registered classification is Class 1 of therapeutic biological products. Up to now, the company has invested a total of about RMB 259 million in R&D on this project.